This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.
Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
All hair in the vitiligo area on the face is white.
Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
Subjects who have previously received depigmentation treatment.